相似文献
1
Angiogenesis inhibitors in the treatment of prostate cancer.
J Hematol Oncol. 2010 Aug 2;3:26. doi: 10.1186/1756-8722-3-26.
2
Angiogenesis inhibitors in prostate cancer therapy.
Discov Med. 2010 Dec;10(55):521-30.
3
Targeting Angiogenesis in Prostate Cancer.
Int J Mol Sci. 2019 May 31;20(11):2676. doi: 10.3390/ijms20112676.
4
Anti-angiogenic therapies in prostate cancer.
Expert Opin Biol Ther. 2013 Jan;13(1):1-5. doi: 10.1517/14712598.2013.733366. Epub 2012 Oct 24.
5
Anti-angiogenesis in prostate cancer: knocked down but not out.
Asian J Androl. 2014 May-Jun;16(3):372-7. doi: 10.4103/1008-682X.125903.
6
Angiogenesis and anti-angiogenic therapy in prostate cancer.
Crit Rev Oncol Hematol. 2013 Aug;87(2):122-31. doi: 10.1016/j.critrevonc.2013.01.002. Epub 2013 Jan 29.
7
Angiogenesis inhibitors in the treatment of prostate cancer.
Chem Immunol Allergy. 2014;99:197-215. doi: 10.1159/000353255. Epub 2013 Oct 17.
8
Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.
Invest New Drugs. 2002 May;20(2):183-94. doi: 10.1023/a:1015626410273.
9
Angiogenesis inhibition in the treatment of prostate cancer.
Anticancer Agents Med Chem. 2009 Dec;9(10):1070-8. doi: 10.2174/187152009789735035.
10
Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
Mol Cell Endocrinol. 2002 Nov 29;197(1-2):239-50. doi: 10.1016/s0303-7207(02)00262-9.
引用本文的文献
1
Translational Pharmacokinetic-Pharmacodynamic Modeling of a Novel Oral Dihydroorotate Dehydrogenase (DHODH) Inhibitor, HOSU-53 (JBZ-001).
Pharmaceutics. 2025 Mar 25;17(4):412. doi: 10.3390/pharmaceutics17040412.
2
Transcriptomic analysis of the anti-tumor effects of leflunomide in prolactinoma.
Sci Rep. 2025 Apr 5;15(1):11703. doi: 10.1038/s41598-025-95509-6.
3
Anoikis in prostate cancer bone metastasis gene signatures and therapeutic implications.
Front Oncol. 2024 Sep 26;14:1446894. doi: 10.3389/fonc.2024.1446894. eCollection 2024.
4
Evidence of the Link between Stroma Remodeling and Prostate Cancer Prognosis.
Cancers (Basel). 2024 Sep 21;16(18):3215. doi: 10.3390/cancers16183215.
5
Design of Nanoparticles in Cancer Therapy Based on Tumor Microenvironment Properties.
Pharmaceutics. 2022 Dec 3;14(12):2708. doi: 10.3390/pharmaceutics14122708.
6
Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies.
Front Oncol. 2022 Jan 10;11:789330. doi: 10.3389/fonc.2021.789330. eCollection 2021.
7
Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments.
Cancers (Basel). 2021 Jun 29;13(13):3263. doi: 10.3390/cancers13133263.
8
Angiogenesis Inhibition in Prostate Cancer: An Update.
Cancers (Basel). 2020 Aug 23;12(9):2382. doi: 10.3390/cancers12092382.
9
Ion Channel Profiling in Prostate Cancer: Toward Cell Population-Specific Screening.
Rev Physiol Biochem Pharmacol. 2021;181:39-56. doi: 10.1007/112_2020_22.
10
The αvβ6 integrin in cancer cell-derived small extracellular vesicles enhances angiogenesis.
J Extracell Vesicles. 2020 May 20;9(1):1763594. doi: 10.1080/20013078.2020.1763594. eCollection 2020.
本文引用的文献
1
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
J Clin Oncol. 2012 May 1;30(13):1534-40. doi: 10.1200/JCO.2011.39.4767. Epub 2012 Mar 26.
2
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
J Clin Oncol. 2011 Oct 20;29(30):4022-8. doi: 10.1200/JCO.2011.35.6295. Epub 2011 Sep 19.
3
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
J Clin Oncol. 2010 Apr 20;28(12):2070-6. doi: 10.1200/JCO.2009.25.4524. Epub 2010 Mar 22.
4
Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001. Epub 2010 Jan 12.
5
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 2010 Feb 4;29(5):625-34. doi: 10.1038/onc.2009.441. Epub 2009 Nov 30.
6
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
Clin Cancer Res. 2009 Oct 1;15(19):6277-83. doi: 10.1158/1078-0432.CCR-09-0717. Epub 2009 Sep 22.
7
Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment.
Jpn J Clin Oncol. 2009 Dec;39(12):833-6. doi: 10.1093/jjco/hyp110. Epub 2009 Sep 22.
8
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.
Br J Cancer. 2009 Oct 20;101(8):1233-40. doi: 10.1038/sj.bjc.6605322. Epub 2009 Sep 15.
9
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
J Clin Oncol. 2009 Oct 1;27(28):4733-40. doi: 10.1200/JCO.2008.19.8721. Epub 2009 Aug 31.
10
Phase II study of sunitinib in men with advanced prostate cancer.
Ann Oncol. 2009 May;20(5):913-20. doi: 10.1093/annonc/mdp111.
Zotero 插件